Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study
Frontiers in Oncology · 08.07.2026 · 16
DOI: 10.3389/fonc.2026.1874863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 08.07.2026. Verfasst von Wenwen Cui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Binzhou People's Hospital Affiliated to Shandong First Medical University, Binzhou, China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Differentiated high-grade thyroid carcinoma (DHGTC) is a newly defined pathological subtype introduced in the 5th edition of the World Health Organization (WHO) Classification of Thyroid Tumors in 2022. This study aimed to analyze its clinicopathological characteristics and improve the understanding of this entity among clinicians and pathologists.
Methods
A total of 19 patients with DHGTC from three tertiary medical centers were retrospectively included. Clinical manifestations, histopathological morphology, immunohistochemical findings, and molecular pathological features were analyzed. Postoperative follow-up data were reviewed to evaluate prognosis, and relevant literature was also reviewed.
Results
Among the 19 patients, 9 were male and 10 were female, with a median age of 61 years (range, 24–78 years). The tumors showed marked invasiveness, with 11 cases involving adjacent structures and 13 cases presenting with lymph node metastasis. All cases exhibited high-grade pathological features, characterized by increased mitotic activity and/or tumor necrosis. The Ki-67 proliferation index was ≥10% in all cases, including 10 cases with a Ki-67 index ≥20%, with the highest value reaching 30%. BRAF abnormalities were identified in 9 cases by molecular testing and/or immunohistochemistry, including aberrant immunohistochemical expression and/or molecular confirmation of the BRAF V600E mutation. In addition, two cases harbored a TERT promoter mutation, and one case showed abnormal p53 expression. During follow-up, 4 patients developed recurrence or metastasis, and 2 patients died.
Conclusions
DHGTC is a highly aggressive thyroid malignancy with a poor prognostic tendency. Increased mitotic activity, tumor necrosis, elevated Ki-67 index, and molecular abnormalities such as BRAF alterations are important for diagnosis and prognostic assessment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Binzhou People's Hospital Affiliated to Shandong First Medical University, Binzhou, China.
- Department of Thyroid Surgery, Binzhou People's Hospital Affiliated to Shandong First Medical University, Binzhou, China.
- Department of Pathology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, China.
- Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Zitieren
APA
Cui, W., Xing, L., Li, Z., Li, X., & Li, J. (2026). Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1874863
Vancouver
Cui W, Xing L, Li Z, Li X, Li J. Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1874863
BibTeX
@article{Cui2026,
author = {Cui, Wenwen and Xing, Lihang and Li, Zhenzhen and Li, Xinjun and Li, Junzhi},
title = {Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1874863}
}
EUVIMED